-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 29, 2024

Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

Author(s)Robert O'Brien, RPh, Diana I. Brixner, PhD, RPh, Ashley Peterson, MHA

Diana Brixner, PhD, highlights the potential for prescription digital therapeutics (PDTs) to have impact in areas such as facilitating behavioral change for mental health conditions and strengthening adherence for complex disease states with intricate drug regimens.

Episodes in this series

Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"

EP. 1 Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"

EP. 2 Payer Needs and Strategies for Evaluating and Covering PDTs

A panel of 4 experts on PDTs

EP. 3 Payers Review Process and Effective Strategies for PDT Coverage

A panel of 4 experts on PDTs

EP. 4 Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Video 5 - "Dawn of the Age of Adopting PDTs"

EP. 5 Dawn of the Age of Adopting PDTs

Video 6 -"Identifying the Most Impactful Disease Areas and Patient Populations for PDTs"

EP. 6 Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

4 KOLs discuss PDTs

EP. 7 Evolving Commercialization and Distribution Models for PDTs

4 KOLs discuss PDTs

EP. 8 Promoting Appropriate PDT Prescribing Through Provider Education and Support

A panel of 4 experts on PDTs

EP. 9 Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

A panel of 4 experts on PDTs

EP. 10 Optimizing Benefit Design and Implementation for Improved PDT Access

A panel of 4 experts on PDTs

EP. 11 PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Claire Harrison | Image Credit: Guy's and St. Thomas' NHS Foundation Trust

INCA033989 Shows Potential as a Targeted Approach for Myelofibrosis With Mutant Calreticulin: Claire Harrison, MD

ByBrooke McCormick,Claire Harrison, MD

July 7th 2026

Dr Amandeep Salhotra | Image Credit: City of Hope

AGAVE-201 Secondary Analysis Supports Bone Health Safety of Axatilimab in Chronic GVHD: Amandeep Salhotra, MD

ByBrooke McCormick,Amandeep Salhotra

July 7th 2026

Image credit: JCP-PROD - stock.adobe.com

Hypoglossal Nerve Stimulation Linked to Reduced Hypoxic Burden in OSA

ByGiuliana Grossi

July 7th 2026

Experts featured in this series.

Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: July 7th 2026 | Updated: June 16th 2026

Experts featured in this series.

The Ripple Effect of Coverage Delays: Patient Harm and Preventable Crises in Psychiatry

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: July 7th 2026 | Updated: June 16th 2026

Trending on AJMC

Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?

340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs

FDA Approves Atacicept for IgA Nephropathy

FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review

Hypoglossal Nerve Stimulation Linked to Reduced Hypoxic Burden in OSA